Multiple myeloma : The Lancet
Links shared publicly online about this topic.
- 1,941total visits
Multiple myeloma : The Lancet
View full resource at thelancet.com
Tags: Multiple Myeloma
Most Recently Shared on June 26, 2009 at 7:03 pm By:
Multiple myeloma - from Lancet - http://bit.ly/bFYn6
Patient R, an MD... | Facebook
facebook.com — “Cancer Survivor Doc wrote: Patient R, an MD with multiple myeloma... Join Facebook to connect with Cancer Survivor Doc and others you may know.” View full resource at facebook.com
Most Recently Shared on May 5, 2012 at 12:54 am By:
Dr. Shani Fox Naturopathic Doctor and CAM
Patient R, an MD with multiple myeloma who's accustomed to eating TV dinners, said today, "Now I see why I'm... http://t.co/fxtbblft
A New Drug Used by 71-Year-Old Marathoner Don Wright Could Soon Be Approved to Help More Patients with Multiple Myeloma Says Tackle Cancer Foundation - Yahoo! Finance
finance.yahoo.com — “From Yahoo! Finance: Leaders of the Tackle Cancer Foundation today said they are excited to learn that a new drug for patients with multiple myeloma, pomalidomide from CELGENE, has been submitted to the Food and Drug Administration.” View full resource at finance.yahoo.com
Most Recently Shared on April 30, 2012 at 1:22 pm By:
A New Drug Used by 71-Year-Old Marathoner Don Wright Could Soon Be Approved to Help More Patients with Multiple ... http://t.co/9KKklv7A
Multiple Myeloma Awareness Bracelet by sweetpea321 on Etsy
etsy.com — “Wrap your wrist in support of multiple myeloma awareness with this beautiful hand-crafted fine Austrian crystal and sterling silver bracelet. This” View full resource at etsy.com
Most Recently Shared on April 12, 2012 at 5:23 am By:
Multiple Myeloma Awareness Bracelet by sweetpea321 http://t.co/rwKdIxgs via @Etsy
Oncology News - Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma |3984613
mdlinx.com — “Oncology Medical Article: Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma” View full resource at mdlinx.com
Most Recently Shared on March 26, 2012 at 1:42 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexame... http://t.co/j626J9jq #oncology
Multiple Myeloma: International Myeloma Foundation
myeloma.org — “Multiple Myeloma: International Myeloma Foundation” View full resource at myeloma.org
Most Recently Shared on March 26, 2012 at 1:01 pm By:
Did you know multiple #myeloma is more prevalent in the US in African Americans than Caucasians? Get informed. Visit http://t.co/RMdPpFLd
Lenalidomide Improves Outcomes in Asymptomatic High-Risk Smoldering and Newly Diagnosed Myeloma
onclive.com — “Continuous treatment with lenalidomide given early prolonged the time to progression, compared with no treatment in patients with high-risk, asymptomatic, smoldering, multiple myeloma.” View full resource at onclive.com
Most Recently Shared on March 23, 2012 at 8:48 pm By:
Early, continuous treatment with Revlimid prolonged the time to progression in patients with smoldering #myeloma http://t.co/2C5Cn060
Oncology News - Prognostic significance of serum cystatin C in multiple myeloma |3990468
mdlinx.com — “Oncology Medical Article: Prognostic significance of serum cystatin C in multiple myeloma” View full resource at mdlinx.com
Most Recently Shared on March 23, 2012 at 7:13 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Prognostic significance of serum cystatin C in multiple myeloma: International Journal of Hematology http://t.co/COP93FTI #oncology
Premotor signs and symptoms of multiple system atrophy : The Lancet Neurology
thelancet.com — “Premotor signs and symptoms of multiple system atrophy. By - Milica Jecmenica-Lukic MD, Prof Werner Poewe MD, Prof Eduardo Tolosa MD, Dr, Prof Gregor K Wenning MD” View full resource at thelancet.com
Most Recently Shared on March 22, 2012 at 9:23 pm By:
Insight into pre-MSA: multiple system atrophy without ataxia or parkinsonism http://t.co/7l59riLR #MSA
Risk of subsequent primary cancer among pr... [Eur J Cancer Prev. 2012] - PubMed - NCBI
ncbi.nlm.nih.gov — “PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on March 22, 2012 at 8:26 pm By:
Physician Relations Health Organization
RT @Myeloma_Doc Patients with prostate cancer have increased risk of second malignancies, including multiple #myeloma http://t.co/I7MOIMdu
Association between pathological and MRI findings in multiple sclerosis : The Lancet Neurology
thelancet.com — “Association between pathological and MRI findings in multiple sclerosis. By - Prof Massimo Filippi MD, Maria A Rocca MD, Prof Frederik Barkhof MD, Prof Wolfgang Brück MD, Jacqueline T Chen PhD, Gia...” View full resource at thelancet.com
Most Recently Shared on March 22, 2012 at 7:49 pm By:
Relationship between pathological & MRI multiple sclerosis findings produces questions along with answers http://t.co/LcSKwAsB
Gregor Wenning: unravelling the mysteries of MSA : The Lancet Neurology
thelancet.com — “Gregor Wenning: unravelling the mysteries of MSA. By - David Holmes” View full resource at thelancet.com
Most Recently Shared on March 22, 2012 at 9:35 am By:
Gregor Wenning, a man in pursuit of multiple system atrophy http://t.co/NUyMjO2H #MSA
Association between pathological and MRI findings in multiple sclerosis : The Lancet Neurology
thelancet.com — “Association between pathological and MRI findings in multiple sclerosis. By - Prof Massimo Filippi MD, Maria A Rocca MD, Prof Frederik Barkhof MD, Prof Wolfgang Brück MD, Jacqueline T Chen PhD, Gia...” View full resource at thelancet.com
Most Recently Shared on March 20, 2012 at 4:18 pm By:
[Review] Association between pathological and MRI findings in multiple sclerosis: The identification of patholog... http://t.co/9i3jbaeO
Addition of Vorinostat to Bortezomib Achieves Modest Improvement in Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
onclive.com — “Vorinostat added to bortezomib improved progression-free survival compared with bortezomib plus placebo in patients with relapsed/refractory multiple myeloma.” View full resource at onclive.com
Most Recently Shared on March 20, 2012 at 2:13 pm By:
Addition of Vorinostat to Bortezomib Achieves Modest Improvement in PFS for Relapsed/Refractory Multiple Myeloma http://t.co/TVDwPrdN
Study: Myeloma Survival Gains, but QOL Slides : IMNG Oncology Report
oncologyreport.com — “The Oncology Report is an independent news source that provides oncologists with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician's practice. The Oncology Report is owned by the International Medical News Group (IMNG) division of Elsevier.” View full resource at oncologyreport.com
Most Recently Shared on March 19, 2012 at 6:39 pm By:
Bob Finn - Medical News Net Health News
Patients with multiple myeloma can live longer, but their quality of life suffers, study says. http://t.co/50XpzIEw
Oncology Medical Article | Two cycles of the PAD combination (PS-341/ Bortezomib, Adriamycin, and Dexamethasone) followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients
mdlinx.com — “Oncology Medical Article: Two cycles of the PAD combination (PS-341/ Bortezomib, Adriamycin, and Dexamethasone) followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients” View full resource at mdlinx.com
Most Recently Shared on March 15, 2012 at 8:34 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Two cycles of the PAD combination (PS-341/ Bortezomib, Adriamycin, and Dexamethasone) followed by auto... http://t.co/hSaf9pCo #oncology
Advertisement
